相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study
Tanya Babich et al.
CLINICAL INFECTIOUS DISEASES (2020)
Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review
Aaron J. Heffernan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Estimation of Extra Length of Stay Attributable to Hospital-Acquired Infections in Adult ICUs Using a Time-Dependent Multistate Model
Robin Ohannessian et al.
CRITICAL CARE MEDICINE (2018)
Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis
J. Nicholas O'Donnell et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014
Ping Yang et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2018)
Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window
Cristina Miglis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
Latania K. Logan et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
Andre C. Kalil et al.
CLINICAL INFECTIOUS DISEASES (2016)
Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies
Yu Zhang et al.
EMERGING MICROBES & INFECTIONS (2016)
Lung Concentrations of Ceftazidime Administered by Continuous versus Intermittent Infusion in Patients with Ventilator-Associated Pneumonia
Joel Cousson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antibiotic-Induced Within-Host Resistance Development of Gram-Negative Bacteria in Patients Receiving Selective Decontamination or Standard Care
Yvonne Noteboom et al.
CRITICAL CARE MEDICINE (2015)
A Systematic Review and Meta- Analyses Show that Carbapenem Use and Medical Devices Are the Leading Risk Factors for CarbapenemResistant Pseudomonas aeruginosa
Anne F. Voor in 't Holt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Matthew E. Falagas et al.
EMERGING INFECTIOUS DISEASES (2014)
Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae
Milena McLaughlin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Impact of Antibiotic Use on Carbapenem Resistance in Pseudomonas aeruginosa: Is There a Role for Antibiotic Diversity?
C. Pluess-Suard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Julio Ramirez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies
Wilhelmina G. Melsen et al.
LANCET INFECTIOUS DISEASES (2013)
Carbapenem antibiotics for serious infections
Peter M. Hawkey et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial
Jong Wook Kim et al.
CRITICAL CARE (2012)
Attributable Mortality of Ventilator-Associated Pneumonia A Reappraisal Using Causal Analysis
Maarten Bekaert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Global Spread of Carbapenemase-producing Enterobacteriaceae
Patrice Nordmann et al.
EMERGING INFECTIOUS DISEASES (2011)
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Antonio T. Freire et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Carbapenem Resistance Among Klebsiella pneumoniae Isolates: Risk Factors, Molecular Characteristics, and Susceptibility Patterns
Khetam Hussein et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials
Mary-Anne W. Aarts et al.
CRITICAL CARE MEDICINE (2008)
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia:: a randomized, open-label, multicenter study
Alvaro Rea-Neto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: A meta-analysis
Effie L. Kuti et al.
JOURNAL OF CRITICAL CARE (2008)
The safety of targeted antibiotic therapy for ventilator-associated pneumonia: A multicenter observational study
Ari R. Joffe et al.
JOURNAL OF CRITICAL CARE (2008)
Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: Diagnosis and treatment
John Muscedere et al.
JOURNAL OF CRITICAL CARE (2008)
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
I. I. Siempos et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit
S. V. Yakovlev et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2006)
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind prospective multicentre study
D. V. Schmitt et al.
INFECTION (2006)
Clinical and economic outcomes of hospital acquired pneumonia in intra-abdominal surgery patients
DA Thompson et al.
ANNALS OF SURGERY (2006)
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
Maniari Joshi et al.
RESPIRATORY MEDICINE (2006)
Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
N Safdar et al.
CRITICAL CARE MEDICINE (2005)
A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia
S Micek et al.
CHEST (2004)
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial
J Chastre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study
M West et al.
CLINICAL THERAPEUTICS (2003)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia
B Maskin et al.
CRITICAL CARE MEDICINE (2002)
Treatment of severe nosocomial pneumonia:: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin
A Torres et al.
THORAX (2000)
分享论文
